Green Light For First OTC Naloxone In US After FDA Raises Caution Flag During Advisory Panel
Executive Summary
Sponsor Emergent revealed single-panel display of instructions at February advisory panel without testing in OTC human factors study. While different naloxone formulations and dosages will remain Rx-only, other Rx 4-mg nasal sprays, available through abbreviated NDAs as generics of Narcan, must transition to OTC, FDA says.
You may also be interested in...
Sweden Seeks To Tackle Opioid Overdose Deaths With Naloxone Rx-To-OTC Switch
Opioid antagonist naloxone will soon be available without prescription in Sweden following a successful Rx-to-OTC application from Norway's DNE Pharma.
The Wait Is Over: US FDA Advisory Committees Returning To In-Person Meetings Come Fall
‘We’re coming back,’ Oncology Center of Excellence Director Richard Pazdur says. Office of New Drugs Director Peter Stein says transition from virtual to in person will be gradual because FDA is trying to be sensitive to adcomm members' need to schedule travel and demands on their time.
OTC Narcan’s Shelf-Life Extended A Year, RiVive Naloxone Shipments Launched To Nonprofits
Emergent extends shelf-life of newly manufactured Narcan from three years to four years at FDA’s request; nonprofit pharma Harm Reduction Therapeutics ships first order of RiVive to overdose prevention advocacy group Remedy Alliance/For the People.